cryptocurrency future in world- Top People searches

Bank of China Securities Guan Tao: As long as the economy is stable and risks are prevented, the spring of China's capital market can be expected. The Central Economic Work Conference will be held in Beijing from December 11th to 12th. Guan Tao, global chief economist of Bank of China Securities, said that the meeting continued the policy thinking since the end of September and emphasized the need to implement more active and promising macro policies. Among them, implementing a more active fiscal policy is an important point to strengthen unconventional countercyclical adjustment. I believe that as long as the economy is stable and risks are prevented, the spring of China's capital market can be expected.Wuzhong, Jiangsu; Dobutamine Hydrochloride Injection and Paramivir Injection are planned to win the bid for the national centralized drug procurement. Jiangsu Wuzhong announced that in the national centralized drug procurement, the bid price of Dobutamine Hydrochloride Injection and Paramivir Injection is 3.58 yuan and 7.47 yuan respectively. The procurement cycle of the two products is until December 31, 2027, and they are supplied to Fujian, Anhui, Jilin, Hubei, Beijing, Inner Mongolia and other provinces and cities respectively. Winning the bid will help to expand the sales of related products, improve market share and brand influence, and have a positive impact on the company's future business performance.CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.

On the 13th, caustic soda dropped by 3.03%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract caustic soda 2501 closed, with a turnover of 57,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 1,383 lots. The total contract turnover of caustic soda futures was 94,800 lots, an increase of 27,900 lots over the previous day. The first 20 seats in the contract held 71,100 lots, an increase of 2,202 lots over the previous day. Short positions in the top 20 seats of the contract were 72,700 lots, an increase of 1,157 lots over the previous day. (Sina Futures)FTSE China A50 index futures fell 2%.On the 13th, coking coal fell by 2.15%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract coking coal closed at 2501, up or down by -2.15%, with a turnover of 104,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 15,553 lots. The total contract turnover of coking coal futures was 180,200 lots, an increase of 8,845 lots over the previous day. The first 20 seats in the contract held 163,200 lots, an increase of 4,563 lots over the previous day. The short positions in the top 20 seats of the contract were 194,300 lots, an increase of 5,926 lots over the previous day. (Sina Futures)

On the 13th, caustic soda dropped by 3.03%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract caustic soda 2501 closed, with a turnover of 57,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 1,383 lots. The total contract turnover of caustic soda futures was 94,800 lots, an increase of 27,900 lots over the previous day. The first 20 seats in the contract held 71,100 lots, an increase of 2,202 lots over the previous day. Short positions in the top 20 seats of the contract were 72,700 lots, an increase of 1,157 lots over the previous day. (Sina Futures)On the 13th, the 30-year treasury bond futures rose by 0.60%, and the latest main contract positions changed as follows. According to the data of the exchange, as of December 13th, the main contract 30-year treasury bond futures closed at 2503, up or down by +0.60%, with a turnover of 71,900 lots. The position data showed that the top 20 seats were clear, and the difference position was 3,777 lots. The total number of 30-year treasury bond futures contracts was 82,700 lots, an increase of 4,416 lots over the previous day. The first 20 seats in the contract held 78,000 lots, a decrease of 1,313 lots from the previous day. The top 20 seats in the contract held 85,000 short positions, a decrease of 1,049 lots from the previous day. (Sina Futures)Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.